EGFR and neoplasm: Clinical and pathological phenotypes associated with BRAFV600E-mutated CRC include proximal tumor location, aggressive growth, unfavorable metastasizing patterns, EGFR blockade resistance, and reduced overall survival (Figure 1) [35].